Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Abbott Says Gets FDA Nod for Lower-Strength HIV Pill
Link ID 700
Title Abbott Says Gets FDA Nod for Lower-Strength HIV Pill
Url http://www.medscape.com/viewarticle/565739?src=rss
Description Abbott Laboratories said it received approval from U.S. health regulators for a new lower-strength tablet formulation of its HIV drug, Kaletra, which is also marketed as Aluvia in developing countries. Reuters Health Information
Category Articles > Business of Medicine
Keywords
Date Nov 14, 2007
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Business of Medicine
1. Undocumented Source of Pharmacy Benefit Manager Revenue
  Pharmacy benefit management companies appeared to pay pharmacies much less per generic-drug transaction than the companies charged employer groups for the same transaction.
American Journal of Health-System Pharmacy
Category:   Articles > Business of Medicine


2. Once-Daily Fluvoxamine Approved for Treatment of SAD and OCD
  The FDA has approved a once-daily extended-release formulation of fluvoxamine maleate for the treatment of social anxiety disorder and obsessive-compulsive disorder. Medscape Medical News
Category:   Articles > Business of Medicine


3. U.S. Medicare Cuts Oxygen, Apnea Pay Rates
  The U.S. government cut Medicare rates for oxygen therapy, sleep apnea and other products, a move likely to hurt Apria Healthcare Group Inc, Lincare Holdings Inc and ResMed Inc. Reuters Health Information
Category:   Articles > Business of Medicine


4. International Approvals: Isentress, Rexin-G, Vectibix
  Europe has approved raltegravir tablets (Isentress); the Philippines has approved a tumor-targeted gene delivery product (Rexin-G); and Europe has approved panitumumab intravenous infusion (Vectibix). Medscape Medical News
Category:   Articles > Business of Medicine


5. Prospects for Renovascular Protection by More Aggressive Renin-Angiotensin System Control
  Aggressive control of the RAS using dual control provides renal and potentially cardiovascular benefits. In clinical trials, telmisartan, the ARB in ONTARGET, has shown renal protective effects.
The Medscape Journal of Medicine
Category:   Articles > Business of Medicine




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS